BRPI0411510A - proteìna, composição farmacêutica, uso da proteìna, polipeptìdeo, uso do mesmo, vetor, ácido nucleico, célula hospedeira, soro policlonal, anticorpo monoclonal, uso de um soro policlonal ou de um anticorpo monoclonal, método para alvejar in vitro uma molécula de interesse com as células que expressam cd11b, células que expressam cd11b, produto de terapia celular para imunizar um ser humano ou um animal contra um antìgeno uso de células que expressam cd11b, e, método para imunizar um paciente contra antìgeno - Google Patents

proteìna, composição farmacêutica, uso da proteìna, polipeptìdeo, uso do mesmo, vetor, ácido nucleico, célula hospedeira, soro policlonal, anticorpo monoclonal, uso de um soro policlonal ou de um anticorpo monoclonal, método para alvejar in vitro uma molécula de interesse com as células que expressam cd11b, células que expressam cd11b, produto de terapia celular para imunizar um ser humano ou um animal contra um antìgeno uso de células que expressam cd11b, e, método para imunizar um paciente contra antìgeno

Info

Publication number
BRPI0411510A
BRPI0411510A BRPI0411510-4A BRPI0411510A BRPI0411510A BR PI0411510 A BRPI0411510 A BR PI0411510A BR PI0411510 A BRPI0411510 A BR PI0411510A BR PI0411510 A BRPI0411510 A BR PI0411510A
Authority
BR
Brazil
Prior art keywords
expressing cells
immunizing
cd11b
protein
monoclonal antibody
Prior art date
Application number
BRPI0411510-4A
Other languages
English (en)
Inventor
Claude Leclerc
Mohammed El-Azami El-Idrissi
Daniel Ladant
Cecile Bauche
Peter Sebo
Jirina Loucka
Radim Osicka
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut
Publication of BRPI0411510A publication Critical patent/BRPI0411510A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01001—Aodenylate cyclase (4.6.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

"PROTEìNA, COMPOSIçãO FARMACêUTICA, USO DA PROTEìNA, POLIPEPTìDEO, USO DO MESMO, VETOR, áCIDO NUCLEICO, CéLULA HOSPEDEIRA SORO POLICLONAL ANTICORPO MONOCLONAL, USO DE UM SORO POLICLONAL OU DE UM ANTICORPO MONOCLONAL, MéTODO PARA ALVEJAR IN VITRO UMA MOLéCULA DE INTERESSE COM AS CéLULAS QUE EXPRESSAM CD11B, CéLULAS QUE EXPRESSAM CD11B, PRODUTO DE TERAPIA CELULAR PARA IMUNIZAR UM SER HUMANO OU UM ANIMAL CONTRA UM ANTìGENO, USO DE CéLULAS QUE EXPRESSAM CD11B, E, MéTODO PARA IMUNIZAR UM PACIENTE CONTRA UM ANTìGENO". A invenção diz respeito às toxinas de adenilato ciclase de Bordetella modificadas que são deficientes quanto à ligação de CD11b/CD18 e ao seu uso na preparação de composição farmacêutica para o tratamento da coqueluche e/ou para a proteção contra a infecção por Bordetella. A invenção também diz respeito aos fragmentos específicos de adenilato ciclase de Bordetella que compreendem o domínio de interação CD11b/CD 18 e ao seu uso, especialmente para alvejar uma molécula de interesse com as células que expressam CD11b.
BRPI0411510-4A 2003-06-18 2004-06-18 proteìna, composição farmacêutica, uso da proteìna, polipeptìdeo, uso do mesmo, vetor, ácido nucleico, célula hospedeira, soro policlonal, anticorpo monoclonal, uso de um soro policlonal ou de um anticorpo monoclonal, método para alvejar in vitro uma molécula de interesse com as células que expressam cd11b, células que expressam cd11b, produto de terapia celular para imunizar um ser humano ou um animal contra um antìgeno uso de células que expressam cd11b, e, método para imunizar um paciente contra antìgeno BRPI0411510A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03291486A EP1489092A1 (en) 2003-06-18 2003-06-18 Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
PCT/EP2004/007811 WO2004113372A1 (en) 2003-06-18 2004-06-18 MODIFIED BORDETELLA ADENYLATE CYCLASE COMPRISING OR LACKING CD11b/CD18 INTERACTION DOMAIN AND USES THEREOF

Publications (1)

Publication Number Publication Date
BRPI0411510A true BRPI0411510A (pt) 2006-07-25

Family

ID=33396035

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411510-4A BRPI0411510A (pt) 2003-06-18 2004-06-18 proteìna, composição farmacêutica, uso da proteìna, polipeptìdeo, uso do mesmo, vetor, ácido nucleico, célula hospedeira, soro policlonal, anticorpo monoclonal, uso de um soro policlonal ou de um anticorpo monoclonal, método para alvejar in vitro uma molécula de interesse com as células que expressam cd11b, células que expressam cd11b, produto de terapia celular para imunizar um ser humano ou um animal contra um antìgeno uso de células que expressam cd11b, e, método para imunizar um paciente contra antìgeno

Country Status (10)

Country Link
US (2) US20060159697A1 (pt)
EP (2) EP1489092A1 (pt)
JP (1) JP4824550B2 (pt)
KR (1) KR20060034645A (pt)
CN (1) CN1839152A (pt)
AU (1) AU2004249431B2 (pt)
BR (1) BRPI0411510A (pt)
CA (1) CA2529565A1 (pt)
RU (1) RU2421241C2 (pt)
WO (1) WO2004113372A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2331348T3 (es) 2000-09-15 2009-12-30 Pasteur Institut Vectores proteinicos para el suministro de moleculas a las celulas que expresan cd11b.
EP1489092A1 (en) 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
EP2193804B1 (en) * 2003-11-21 2015-12-23 Institut Pasteur Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens
PL1576967T3 (pl) 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
CN101636157A (zh) * 2007-01-12 2010-01-27 康乃尔研究基金会有限公司 作为抗菌干预的新型靶的腺苷酰环化酶
CN101680026A (zh) * 2007-01-12 2010-03-24 康乃尔研究基金会有限公司 作为真核病原体感染治疗的新型靶的腺苷酰环化酶
PL2233569T3 (pl) 2009-03-23 2015-02-27 Pasteur Institut Zmutowane polipeptydy cyaa i pochodne polipeptydu odpowiednie do dostarczania cząsteczek immunogennych do komórki
CN102439146A (zh) * 2009-03-23 2012-05-02 巴斯德研究院 适合将免疫原性分子递送到细胞中的突变CyaA多肽及多肽衍生物
RU2471868C2 (ru) * 2010-02-18 2013-01-10 Закрытое акционерное общество "Научно-исследовательский институт "Аджиномото-Генетика" (ЗАО АГРИ) Мутантная аденилатциклаза, днк, кодирующая ее, бактерия семейства enterobacteriaceae, содержащая указанную днк, и способ получения l-аминокислот
EP2618668B1 (en) 2010-09-20 2016-09-14 Wisconsin Alumni Research Foundation Mosquitocidal xenorhabdus, lipopeptide and methods
EP2690172A1 (en) 2012-07-23 2014-01-29 Genticel CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses
EP2689786A1 (en) 2012-07-23 2014-01-29 Genticel HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders
WO2016094438A1 (en) * 2014-12-08 2016-06-16 Board Of Regents, The University Of Texas System Bordetella adenylate cyclase toxin vaccines and neutralizing antibodies
CN108025053A (zh) * 2015-04-16 2018-05-11 创赏有限公司 百日咳杆菌免疫原性的疫苗组合物
WO2018091613A1 (en) 2016-11-17 2018-05-24 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
US20180133301A1 (en) * 2016-11-17 2018-05-17 École National Vétérinaire de Toulouse (E.N.V.T.) Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
EP3323426A1 (en) 2016-11-17 2018-05-23 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
EP3342421A1 (en) 2016-12-27 2018-07-04 Genticel Immunogenic composition comprising cyaa-derived polypeptide promoting a th1/th17-oriented immune response
CN110711205A (zh) * 2018-07-13 2020-01-21 北京中台恒基生物技术有限公司 一种肿瘤疫苗及其制备方法
EP3616717A1 (en) * 2018-08-31 2020-03-04 Mikrobiologicky ustav AV CR, v.v.i. Recombinant antigen inducing antibodies for neutralization of bordetella adenylate cyclase toxin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638169B1 (fr) * 1988-10-25 1991-01-11 Pasteur Institut Derives d'adenyl cyclase et leurs utilisations biologiques
WO1991008294A1 (en) * 1989-11-29 1991-06-13 Smithkline Beecham Biologicals (S.A.) Novel vaccine
WO1993021324A1 (en) * 1992-04-21 1993-10-28 Institut Pasteur Recombinant mutants for inducing specific immune responses
FR2736064B1 (fr) * 1995-06-30 1997-09-05 Pasteur Institut Epitopes protecteurs de l'adenyl cyclase-hemolysine(ac-hty). leur application au traitement ou a la prevention des infections par bordetella
DE69736709T2 (de) * 1996-07-02 2007-10-04 Sanofi Pasteur Ltd., Toronto Vielwertige dtp-polio-impfstoffe
ES2331348T3 (es) * 2000-09-15 2009-12-30 Pasteur Institut Vectores proteinicos para el suministro de moleculas a las celulas que expresan cd11b.
EP1489092A1 (en) 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof

Also Published As

Publication number Publication date
CN1839152A (zh) 2006-09-27
KR20060034645A (ko) 2006-04-24
EP1633776B1 (en) 2017-08-09
JP2007527697A (ja) 2007-10-04
AU2004249431B2 (en) 2009-11-05
US20060159697A1 (en) 2006-07-20
WO2004113372A1 (en) 2004-12-29
US7906123B1 (en) 2011-03-15
RU2421241C2 (ru) 2011-06-20
EP1489092A1 (en) 2004-12-22
CA2529565A1 (en) 2004-12-29
AU2004249431A1 (en) 2004-12-29
RU2006101326A (ru) 2006-07-27
JP4824550B2 (ja) 2011-11-30
EP1633776A1 (en) 2006-03-15

Similar Documents

Publication Publication Date Title
BRPI0411510A (pt) proteìna, composição farmacêutica, uso da proteìna, polipeptìdeo, uso do mesmo, vetor, ácido nucleico, célula hospedeira, soro policlonal, anticorpo monoclonal, uso de um soro policlonal ou de um anticorpo monoclonal, método para alvejar in vitro uma molécula de interesse com as células que expressam cd11b, células que expressam cd11b, produto de terapia celular para imunizar um ser humano ou um animal contra um antìgeno uso de células que expressam cd11b, e, método para imunizar um paciente contra antìgeno
Murphy et al. Five alpha-D-galactopyranosyl-binding isolectins from Bandeiraea simplicifolia seeds.
Prasadarao et al. A novel interaction of outer membrane protein A with C4b binding protein mediates serum resistance of Escherichia coli K1
Cerra et al. Three soluble rat beta-galactoside-binding lectins.
DE69520739T2 (de) Konjugat aus einem modifizierten superantigen und einer zielsuchenden verbindung und die verwendung des konjugats
Schmidt et al. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors
BR0214137A (pt) Anticorpos para o cd40, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento, linhagem, de célula isolada, molécula de ácido nucléico isolada, vetor compreendendo a mesma, célula hospedeira e método de fabricação dos referidos anticorpos
Winter et al. The mushroom Marasmius oreades lectin is a blood group type B agglutinin that recognizes the Galα1, 3Gal and Galα1, 3Galβ1, 4GlcNAc porcine xenotransplantation epitopes with high affinity
CA2538619A1 (en) Re-targeted toxin conjugates
BRPI0418766B8 (pt) anticorpo ou seu fragmento, vetor, composição farmacêutica, ensaio e método para detectar a presença de proteína steap-1, bem como método para distribuir um agente citotóxico ou um agente de diagnóstico
Zewe et al. Cloning and cytotoxicity of a human pancreatic RNase immunofusion
BRPI0412567A (pt) anticorpo humano isolado, método de tratamento de uma condição causada pela expressão aumentada de ngf ou pela sensibilidade aumentada ao ngf em um paciente, composição farmacêutica, método para detectar ngf em uma amostra biológica, molécula de ácido nucleico, célula hospedeira, linhagem celular isolada, agente de ligação especìfica em ngf, anticorpo humano isolado ou fragmento de imunoglobulina imunologicamente funcional ou um ligante de antìgeno do mesmo, polinucleotìdeo, vetor de expressão, medicamento para tratar um distúrbio doloroso ou uma condição associada com a expressão aumentada de ngf ou a sensibilidade aumentada ao ngf, e, uso de uma quantidade farmaceuticamente efetiva de anticorpo
JP2003505343A (ja) ボツリヌス神経毒を含む治療薬
BRPI0512911A (pt) anticorpo humano isolado, ácido nucléico, vetor, célula, método de produzir um anticorpo anti-kir humano, composição farmacêutica, e, método de potenciar a atividade da célula nk em um paciente em necessidade do mesmo
PL201879B1 (pl) Białko hybrydowe i jego zastosowanie
Steeves et al. Identification of three oligosaccharide binding sites in ricin
Poon et al. Identification of binding domains in the sodium channel NaV1. 8 intracellular N-terminal region and annexin II light chain p11
US20190071706A1 (en) Compositions and methods for preventing and treating disease
Bachran et al. Inhibition of tumor growth by targeted toxins in mice is dramatically improved by saponinum album in a synergistic way
BR0113915A (pt) Uso de adenil ciclase da espécie bordetella, composição imunogênica ou farmacêutica, uso da mesma, e , vetor proteináceo
BR0010155A (pt) Proteìnas isolada, e quimérica, composição, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição de vacina recombinante ou composição de vacina atenuada, composição farmacêutica, métodos de imunizar um indivìduo contra um imunógeno, proteìna não-cd80 isolada, molécula de ácido nucleico, e, método de imunossuprimir um indivìduo
Liu et al. Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A
Travaglione et al. Epithelial cells and expression of the phagocytic marker CD68: scavenging of apoptotic bodies following Rho activation
Ghohestani et al. Crescentic glomerulonephritis and subepidermal blisters with autoantibodies to α5 and α6 chains of type IV collagen
Tikkanen et al. Purification of a Galactosyl-α1-4-galactose-binding Adhesin from the Gram-positive Meningitis-associated Bacterium Streptococcus suis

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]